ArticleJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2019
Mendelian Randomization Analysis Reveals a Causal Influence of Circulating Sclerostin Levels on Bone Mineral Density and Fractures.
Article in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a Genome-Wide Association Meta-Analysis Followed by Mendelian Randomization.Arthritis & rheumatology (Hoboken, N.J.) · 2023Pooled it
- GWAS meta-analysis followed by Mendelian randomization revealed potential control mechanisms for circulating α-Klotho levels.Human molecular genetics · 2022Pooled it
- Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics.Science translational medicine · 2020Pooled it
- Article
- Genetic liability to childhood Kawasaki disease and adult cardiovascular outcomes.Frontiers in cardiovascular medicine · 2026Article
- Leveraging Proteomics and Proteogenomics for Understanding Osteoporosis and Other Musculoskeletal Diseases.Current osteoporosis reports · 2025Review
- Reply.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- Sclerostin and Cardiovascular Disease.Current osteoporosis reports · 2023Review
- Early sclerostin assessment in frail elderly patients with sepsis: insights on short- and long-term mortality prediction.Internal and emergency medicine · 2023Article
- Determinants of bone mass in older adults with normal- and overweight derived from the crosstalk with muscle and adipose tissue.Scientific reports · 2023Article
- Hyperthyroidism and Wnt Signaling Pathway: Influence on Bone Remodeling.Metabolites · 2023Review
- A Guide for Understanding and Designing Mendelian Randomization Studies in the Musculoskeletal Field.JBMR plus · 2022Review
- Towards a cure for osteoporosis: the UK Royal Osteoporosis Society (ROS) Osteoporosis Research Roadmap.Archives of osteoporosis · 2022Article
- Sclerostin Downregulation Globally by Naturally Occurring Genetic Variants, or Locally in Atherosclerotic Plaques, Does Not Associate With Cardiovascular Events in Humans.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2021Article
- Skeletal endocrinology: where evolutionary advantage meets disease.Bone research · 2021Review
- Sclerostin and Osteocalcin: Candidate Bone-Produced Hormones.Frontiers in endocrinology · 2021Review
- Cytokines CCL2 and CXCL1 may be potential novel predictors of early bone loss.Molecular medicine reports · 2020Article
- Opportunities and Challenges in Functional Genomics Research in Osteoporosis: Report From a Workshop Held by the Causes Working Group of the Osteoporosis and Bone Research Academy of the Royal Osteoporosis Society on October 5th 2020.Frontiers in endocrinology · 2020Review
- Use of Mendelian Randomization to Examine Causal Inference in Osteoporosis.Frontiers in endocrinology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 14 institutions in 9 countries.
Funding
Abstract
In bone, sclerostin is mainly osteocyte-derived and plays an important local role in adaptive responses to mechanical loading. Whether circulating levels of sclerostin also play a functional role is currently unclear, which we aimed to examine by two-sample Mendelian randomization (MR). A genetic instrument for circulating sclerostin, derived from a genomewide association study (GWAS) meta-analysis of serum sclerostin in 10,584 European-descent individuals, was examined in relation to femoral neck bone mineral density (BMD; n = 32,744) in GEFOS and estimated bone mineral density (eBMD) by heel ultrasound (n = 426,824) and fracture risk (n = 426,795) in UK Biobank. Our GWAS identified two novel serum sclerostin loci, B4GALNT3 (standard deviation [SD]) change in sclerostin per A allele (β = 0.20, p = 4.6 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.